-

The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines

MADRID--(BUSINESS WIRE)--The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Medicines1.

This cardiovascular polypill includes three active ingredients (acetylsalicylic acid, ramipril and atorvastatin) and has been proven to be effective in preventing cardiovascular events after a heart attack, reducing mortality from cardiovascular causes by 33%. This was evidenced by the SECURE2 study, with results published in August 2022 in the New England Journal of Medicine3 (NEJM).

“The SECURE results showed, for the first time, that the cardiovascular polypill developed by the CNIC and Ferrer achieves clinically relevant reductions in recurrent cardiovascular events in patients who have suffered a myocardial infarction,” said Dr. Valentín Fuster, principal investigator of the study, General Director of the CNIC, President of Mount Sinai Heart and Physician-in-Chief of Mount Sinai Hospital, New York.

As stated in the WHO report, “essential medicines are those that satisfy the priority health care needs of a population. They are intended to be available in functioning health systems at all times, in appropriate dosage forms, of assured quality and at prices individuals and health systems can afford.”

According to Oscar Pérez, Chief Marketing, Market Access and Business Development Officer at Ferrer, “the 33% reduction in cardiovascular mortality demonstrates the efficacy of treatment with Trinomia4 compared to standard treatment. The inclusion of this therapeutic solution in the WHO's List of Essential Medicines confirms our aim to make a positive impact in society and is an important step in our mission to bring significant and differential value to people with cardiovascular disease.”

Currently, the cardiovascular polypill developed by the CNIC and Ferrer is marketed in 25 countries and the feasibility of extending its distribution to additional territories, including the United States, is under analysis.

Bibliographical references:

1.- https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02

2.- SECURE study - https://www.cnic.es/en/clinical-research

3.- Polypill Strategy in Secondary Cardiovascular Prevention, Castellano JM, Fuster V et al. New England Journal of Medicine (NEJM). 2022 Aug. (consult: https://www.nejm.org/doi/full/10.1056/NEJMoa2208275)

4.- Trinomia® data sheet: SUMMARY OF PRODUCT CHARACTERISTICS (https://www.ferrer.com/sites/default/files/2023-08/Trinomia_SmPC.pdf)

Contacts

For more information:
gortizdez@ferrer.com
+34 936 003 779
Communication Advisor at Ferrer

Ferrer

Details
Headquarters: Barcelona, Spain
CEO: Mario Rovirosa
Employees: 1.800
Organization: PRI


Contacts

For more information:
gortizdez@ferrer.com
+34 936 003 779
Communication Advisor at Ferrer

More News From Ferrer

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

BARCELONA, Spain--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patie...

Ferrer is the Highest-performing Pharmaceutical Company in the World for Social and Environmental Impact According to B Corp

BARCELONA, Spain--(BUSINESS WIRE)--Spanish pharmaceutical company Ferrer has reaffirmed its status as a B Corp, an international certification awarded to companies that operate with a business model centered on positive impact and meet high social, environmental, and community standards. Ferrer has achieved a score of 136.4 points, making it the highest-rated pharmaceutical company in the world. Additionally, it now ranks as the third-highest scoring company across all sectors globally among th...

Ferrer is Recognized for Its Best-in-class Ethics and Compliance Program

BARCELONA, Spain--(BUSINESS WIRE)--Ferrer has achieved Compliance Leader Verification™, the prestigious recognition granted by Ethisphere, which distinguishes the pharmaceutical company as a global leader in upholding ethical and responsible corporate practices in its business operations. Ethisphere is a leading organization dedicated to advancing ethical business practices, and its recognition acknowledges organizations with an outstanding commitment to robust ethics and compliance programs. T...
Back to Newsroom